Skip to main content
Clinical Trials/ISRCTN48886202
ISRCTN48886202
Active, not recruiting
Phase 2

Prospective clinical study to evaluate the safety and efficacy of the Versius surgical system in robot-assisted cholecystectomy

CMR Surgical (United Kingdom)0 sites30 target enrollmentApril 13, 2023

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
CMR Surgical (United Kingdom)
Enrollment
30
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 13, 2023
End Date
November 1, 2023
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
CMR Surgical (United Kingdom)

Eligibility Criteria

Inclusion Criteria

  • 1\. Patient deemed suitable for laparoscopic cholecystectomy procedure using Versius Surgical Robotic System
  • 2\. Patients able to provide written informed consent to participate in the study (with help of appropriate legal representatives if required)
  • 3\. Male or female, aged 18 years or above
  • 4\. Females of childbearing potential must not be pregnant and agree to not become pregnant for the duration of the study
  • 5\. Patients with BMI \<40 kg/m². Priority BMI 25 to 40 kg/m²

Exclusion Criteria

  • 1\. Patient participation in an investigational clinical study within 30 days before screening
  • 2\. Inability or difficulties to provide informed consent
  • 3\. Oncological cases: patients undergoing surgery or treatment for malignant disease
  • 4\. Patients who fall into the American Society of Anaesthesiologists (ASA) Class IV or above
  • 5\. History of chronic alcohol or drug abuse
  • 6\. Chronic renal failure or on dialysis
  • 7\. Significant medical history or immunocompromised
  • 8\. Subjects with any other clinically significant unstable medical disorder, life\-threatening disease, or anything else in the opinion of the Investigator which would contra\-indicate a surgical procedure
  • 9\. Patient tested COVID positive within the last 30 days of screening
  • 10\. Patient tested COVID positive within 48 hours of the procedure

Outcomes

Primary Outcomes

Not specified

Similar Trials